CDNA — CareDx, Inc.

Is CDNA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

CareDx, Inc. (CDNA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $46.51. The rating moved from Neutral to Overbought on August 17, 2026.

See all overbought Healthcare stocks →

AI analysis

CareDx, Inc. (CDNA) is well positioned in the transplant-diagnostics niche with recurring-test revenue, validated clinical evidence, and scalable lab/sales operations that support continued adoption of non-invasive surveillance. Near-term performance will depend on transplant procedure volumes, payer negotiations, and execution on international and cross-sell initiatives. Sector-level tailwinds for diagnostics and an active M&A environment provide upside optionality, while reimbursement dynamics and competitive pressure remain the primary constraints on faster margin and top-line expansion.

Key factors

  • Market leadership in transplant diagnostics with established commercial products (e.g., donor-derived cell-free DNA and gene-expression surveillance) supporting recurring revenue
  • Growing clinical adoption of non-invasive transplant surveillance that can replace or reduce biopsy frequency, driving test volume growth over time
  • Strong clinical evidence and guideline traction relative to earlier-stage competitors, helping commercial uptake and payer conversations
  • Operational scale of centralized labs and salesforce that enable cross-selling of product portfolio and international expansion opportunities
  • Favorable diagnostic & screening thematic tailwinds as AI-enabled and non-invasive diagnostics gain traction, supporting long-term market expansion
  • M&A and strategic partnership environment in biotech/diagnostics remains active, potentially creating optionality or valuation catalysts

Risks

  • Reimbursement and payer pressure, including Medicare Advantage distribution shifts and payer rationalization that could compress realized test pricing
  • Competition from rivals (including Natera/Prospera and other molecular diagnostics players) that could pressure market share and pricing
  • Volatility in transplant procedure volumes (macroeconomic or COVID-like disruptions) that would directly affect addressable test volumes
  • Regulatory, compliance, or lab-operational issues that could interrupt testing capacity or increase costs
  • Execution risk on international expansion and salesforce productivity, which are needed to sustain higher growth rates
  • General market and interest-rate sensitivity that can compress multiples for growth diagnostic names and delay M&A outcomes

See today's live rating, score and targets

Members see the live hourly rating for CDNA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.